BioInvent International has announced the appointment of Marie Moores as Chief Operating Officer.
Marie Moores joined the company on February 1, 2022, and she will be involved in all operational aspects including quality assurance as well as commercial strategy planning such as further developing the target product profiles for BioInvent’s drug candidates.
Marie Moores has over 25 years’ experience of transforming international organizations, with expertise in regulatory affairs and building businesses focusing on drug development. Before joining BioInvent she has been Executive Vice President, International Operations & Early Development at the Norwegian company LINK Medical Research. She previously spent more than 20 years with Theradex Oncology as Director, Clinical and Regulatory Operations for Europe, growing the business from four people to more than sixty and leading the creation of a profitable business.
“As BioInvent’s COO, Marie’s regulatory and drug development experience will be very valuable as we continue to expand our pipeline of promising anti-cancer treatments. With soon four products progressing through five clinical trials, Marie will take some of the important responsibility for the day-to-day operations. This will allow me to devote more of my time to the broader, longer-term perspective, focusing on strategic development, new partnerships, and capital markets,” says Martin Welschof, CEO of BioInvent.
Photo of Marie Moores: BioInvent